Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Regulatory Update: GlaxoSmithKline receives Complete Response letter from FDA for candidate meningococcal and Hib combination vaccine
GSK announced it's received a Complete Response letter from FDA for MenHibrix ,active immunization of infants 6 weeks through 15 months
-
Lucozade to help drive Vodafone McLaren Mercedes performance
Ahead of Singapore Grand Prix, Lucozade announces an innovative performance partnership with the Vodafone McLaren Mercedes Formula 1 team.
-
GlaxoSmithKline (GSK) and McLaren Group announce innovative strategic partnership
GSK announced it's formed a partnership with McLaren Group which will run initially until 2016 focusing on innovation and high-tech research
-
GlaxoSmithKline (GSK) commits $1 million in cervical cancer vaccine to new cooperative effort aimed at reducing deaths from women's cancers
GSK has committed $1 million in Cervarix, cervical cancer vaccine to the Pink Ribbon Red Ribbon partnership over the next five years.
-
GlaxoSmithKline and Amicus Therapeutics commence second phase III study of Amigal™ for Fabry disease
GlaxoSmithKline and Amicus Therapeutics commence second phase III study of Amigal™ for Fabry disease
-
GSK gives update on agreement with World Health Organization to support de-worming of school age children in endemic countries
First African countries, Togo and Rwanda, receive albendazole donations to scale-up school based de-worming programmes for children at risk.
-
Lapatinib clinical trial update
Review - Phase III study of lapatinib & trastuzumab in patients with HER2+ early stage breast cancer to continue trials without modification
-
Jens Eckstein named President of SR One, GSK’s venture healthcare group
Jens Eckstein has been named President of SR One, GSK's independent healthcare venture organisation, effective 1 October.
-
GlaxoSmithKline (GSK) shows sign of things to come at London 2012 Olympic and Paralympic Games
2012 provider, GSK, unveils sign celebrating its scientific contribution to the Games
-
GSK awarded contract by BARDA to support research on potential novel antibiotic
GSK & BARDA's contract to support the development of a potentially new antibiotic against hospital Gram negative and biothreat pathogens.
-
GSK takes minority stake in new spin out Autifony Therapeutics
GSK announced its wholly-owned subsidiary will receive 25.4% equity stake in Autifony Therapeutics Limited alongside other investors.
-
GSK and Impax announce positive topline results of ASCEND-PD Phase III study of IPX066 in Advanced Parkinson’s disease
IPX066 demonstrated statistically significant improvement over carbidopa-levodopa plus entacapone in reducing off time % during waking hours
-
GSK and Enigma Diagnostics announce collaboration on assay development and commercialisation of Enigma’s ML platform
GSK & Enigma announced agreements for the supply of Enigma ML system for respiratory tests for use on its real-time PCR technology platform.
-
Regulatory Update: GSK and XenoPort submit supplemental New Drug Application to FDA for Horizant™ in postherpetic neuralgia
GSK & XNPT announced sNDA submitted to FDA for approval of Horizant tablets for the management of PHN in adults.
-
Regulatory update – Stiefel, a GSK company, files NDA for tazarotene foam
Stiefel announced it's submitted a NDA to the FDA for tazarotene foam for the topical treatment of facial acne vulgaris in patients 12+.
-
GSK delivers strong Q2 performance with underlying sales growth* of 5%, increased pipeline visibility and dividend of 16p, up 7%
Full details of GSK's results for the second quarter of 2011 can be found in the
-
GlaxoSmithKline European regulatory update on Pandemrix™
GSK announced EMA's CHMP has recommended an update to the product label for the H1N1 influenza vaccine, Pandemrix.
-
GlaxoSmithKline and Human Genome Sciences receive European authorisation for Benlysta® (belimumab)
GSK & HSG announced, EC has granted marketing authorisation for Benlysta as therapy in patients with active autoantibody-positive SLE.
-
EU and US Regulatory Update - Votrient® (pazopanib)
GSK announced it's submitted a Marketing Authorisation Application to EMA for Votrient, the treatment of patients with advanced STR.
-
London 2012 partner, GlaxoSmithKline, shares scientific expertise with World Anti-Doping Agency to help fight against abuse of drugs in sport
GSK signed a long-term agreement with WADA helping create early detection methods for performance-enhancing medicines in sport.
